Login to Your Account

Financings Roundup

Inhibitex Expects $44M+ Net for INX-189 Hep C Phase II

By Tom Wall

Friday, April 8, 2011
Inhibitex Inc. expects to net about $44 million through a public offering of 11.46 million shares of common stock at $4.10 per share for a Phase II trial of nucleotide polymerase inhibitor INX-189 for chronic hepatitis C and other R&D and corporate expenses.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription